ArticleJournal of patient-reported outcomes2026
Psychometric properties of the Chronic Rhinosinusitis Patient-Reported Outcome (CRS-PRO) questionnaire in a Spanish population.
Article in Journal of patient-reported outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the psychometric properties of the Spanish version of the Chronic Rhinosinusitis Patient-Reported Outcome (CRS-PRO) measure in patients with chronic rhinosinusitis (CRS), including those with and without nasal polyps.
methodsA cross-sectional validation study was conducted with 124 CRS patients recruited from a tertiary otolaryngology center. Internal consistency (Cronbach’s α), test–retest reliability (ICC), construct validity (exploratory factor analysis), concurrent validity (Pearson correlation with NPQ, NOSE-E, and SNOT-22), and discriminative capacity (ROC curve analysis) were assessed. A subsample of 35 patients completed the CRS-PRO twice to evaluate reproducibility.
resultsFactor analysis confirmed a three-factor structure (rhinologic symptoms, psychosocial impact, and facial discomfort), explaining 69.4% of the variance. Internal consistency was excellent (α = 0.874), and test–retest reliability was very high (ICC = 0.986; SEM = 2; MDC95 = 3). All items demonstrated moderate to high item-total correlations. The CRS-PRO strongly correlated with NPQ (r = 0.848), NOSE-E (r = 0.849), and SNOT-22 (r = 0.803). ROC analysis yielded an AUC of 0.929, with an optimal cut-off point of > 22 points (sensitivity 86.67%, specificity 86.08%) to identify severe symptom burden.
conclusionsThe Spanish CRS-PRO is a valid, reliable, and efficient instrument for assessing disease-specific quality of life in CRS. Its strong psychometric performance, brevity, and diagnostic accuracy support its use in routine clinical practice, research, and digital health applications. These findings establish the CRS-PRO as a core PROM for Spanish-speaking patients with CRS. CLINICAL
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.